Analysis of Liquidity Ratios
Quarterly Data
Liquidity ratios measure the company ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Edwards Lifesciences Corp., liquidity ratios (quarterly data)
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Edwards Lifesciences Corp. current ratio deteriorated from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Edwards Lifesciences Corp. quick ratio deteriorated from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Edwards Lifesciences Corp. cash ratio improved from Q2 2021 to Q3 2021 but then deteriorated significantly from Q3 2021 to Q4 2021. |
Current Ratio
Edwards Lifesciences Corp., current ratio calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Current assets | 3,180,700) | 3,515,500) | 3,322,900) | 3,069,200) | 3,091,000) | 2,980,400) | 2,690,300) | 2,507,900) | 2,984,000) | 2,739,700) | 2,354,700) | 2,368,800) | 2,286,900) | 2,912,600) | 2,696,000) | 2,716,900) | 2,532,100) | 2,566,400) | 2,283,400) | 2,018,400) | ||||||
| Current liabilities | 1,032,300) | 966,500) | 886,200) | 799,000) | 893,900) | 846,300) | 873,200) | 746,900) | 902,400) | 775,800) | 697,000) | 646,500) | 876,600) | 1,261,100) | 1,183,200) | 1,314,500) | 1,402,900) | 735,200) | 562,500) | 584,800) | ||||||
| Liquidity Ratio | ||||||||||||||||||||||||||
| Current ratio1 | 3.08 | 3.64 | 3.75 | 3.84 | 3.46 | 3.52 | 3.08 | 3.36 | 3.31 | 3.53 | 3.38 | 3.66 | 2.61 | 2.31 | 2.28 | 2.07 | 1.80 | 3.49 | 4.06 | 3.45 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Current Ratio, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | 1.85 | 1.83 | 1.79 | 1.75 | 1.72 | 1.70 | 1.57 | 1.43 | 1.44 | 1.54 | 1.68 | 1.58 | — | — | — | — | — | — | — | — | ||||||
| Cigna Group | 0.83 | 0.70 | 0.72 | 0.76 | 0.77 | 0.79 | 0.83 | 0.76 | 0.74 | 0.61 | 0.65 | 0.64 | — | — | — | — | — | — | — | — | ||||||
| CVS Health Corp. | 0.88 | 0.94 | 0.95 | 0.93 | 0.91 | 0.95 | 0.98 | 0.99 | 0.94 | 0.92 | 0.95 | 0.95 | — | — | — | — | — | — | — | — | ||||||
| Elevance Health Inc. | 1.47 | 1.48 | 1.49 | 1.57 | 1.55 | 1.59 | 1.64 | 1.53 | 1.65 | 1.70 | 1.64 | 1.61 | — | — | — | — | — | — | — | — | ||||||
| Humana Inc. | 1.62 | 1.72 | 1.71 | 1.67 | 1.77 | 1.81 | 1.69 | 1.66 | 1.82 | 1.83 | 1.75 | 1.65 | — | — | — | — | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 5.08 | 5.58 | 5.99 | 6.71 | 6.86 | 7.04 | 6.38 | 4.96 | 4.53 | 4.64 | 5.04 | 5.44 | — | — | — | — | — | — | — | — | ||||||
| Medtronic PLC | 2.65 | 2.10 | 2.16 | 1.87 | 2.13 | 2.75 | 2.77 | 2.67 | 2.59 | 2.36 | 2.56 | 2.46 | — | — | — | — | — | — | — | — | ||||||
| UnitedHealth Group Inc. | 0.79 | 0.77 | 0.77 | 0.74 | 0.74 | 0.82 | 0.84 | 0.75 | 0.69 | 0.70 | 0.67 | 0.73 | — | — | — | — | — | — | — | — | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Current ratio = Current assets ÷ Current liabilities
= 3,180,700 ÷ 1,032,300 = 3.08
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Edwards Lifesciences Corp. current ratio deteriorated from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Quick Ratio
Edwards Lifesciences Corp., quick ratio calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Cash and cash equivalents | 862,800) | 1,506,900) | 1,312,800) | 1,174,200) | 1,183,200) | 1,024,000) | 903,500) | 662,900) | 1,179,100) | 1,186,600) | 726,800) | 709,200) | 714,100) | 1,261,300) | 1,226,400) | 1,227,000) | 818,300) | 630,300) | 508,200) | 819,300) | ||||||
| Short-term investments | 604,000) | 287,800) | 248,400) | 156,400) | 219,400) | 271,300) | 260,300) | 368,200) | 337,800) | 170,300) | 207,500) | 253,800) | 242,400) | 334,400) | 174,400) | 272,300) | 519,200) | 772,500) | 623,600) | 98,900) | ||||||
| Accounts receivable, net of allowances | 582,200) | 600,600) | 640,500) | 586,600) | 514,600) | 549,700) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | ||||||
| Other receivables | 82,700) | 63,600) | 59,800) | 77,700) | 88,200) | 122,000) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | ||||||
| Accounts and other receivables, net of allowances (legacy) | —) | —) | —) | —) | —) | —) | 567,900) | 585,100) | 599,100) | 570,000) | 609,600) | 578,000) | 537,300) | 530,100) | 520,100) | 446,800) | 462,200) | 475,000) | 510,700) | 510,200) | ||||||
| Total quick assets | 2,131,700) | 2,458,900) | 2,261,500) | 1,994,900) | 2,005,400) | 1,967,000) | 1,731,700) | 1,616,200) | 2,116,000) | 1,926,900) | 1,543,900) | 1,541,000) | 1,493,800) | 2,125,800) | 1,920,900) | 1,946,100) | 1,799,700) | 1,877,800) | 1,642,500) | 1,428,400) | ||||||
| Current liabilities | 1,032,300) | 966,500) | 886,200) | 799,000) | 893,900) | 846,300) | 873,200) | 746,900) | 902,400) | 775,800) | 697,000) | 646,500) | 876,600) | 1,261,100) | 1,183,200) | 1,314,500) | 1,402,900) | 735,200) | 562,500) | 584,800) | ||||||
| Liquidity Ratio | ||||||||||||||||||||||||||
| Quick ratio1 | 2.07 | 2.54 | 2.55 | 2.50 | 2.24 | 2.32 | 1.98 | 2.16 | 2.34 | 2.48 | 2.22 | 2.38 | 1.70 | 1.69 | 1.62 | 1.48 | 1.28 | 2.55 | 2.92 | 2.44 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Quick Ratio, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | 1.28 | 1.25 | 1.19 | 1.16 | 1.14 | 1.01 | 0.93 | 0.83 | 0.88 | 0.93 | 0.98 | 0.94 | — | — | — | — | — | — | — | — | ||||||
| Cigna Group | 0.48 | 0.58 | 0.59 | 0.64 | 0.66 | 0.46 | 0.50 | 0.42 | 0.41 | 0.51 | 0.53 | 0.53 | — | — | — | — | — | — | — | — | ||||||
| CVS Health Corp. | 0.55 | 0.59 | 0.58 | 0.54 | 0.53 | 0.58 | 0.63 | 0.60 | 0.52 | 0.52 | 0.54 | 0.55 | — | — | — | — | — | — | — | — | ||||||
| Elevance Health Inc. | 1.33 | 1.33 | 1.35 | 1.43 | 1.42 | 1.45 | 1.49 | 1.37 | 1.52 | 1.58 | 1.51 | 1.49 | — | — | — | — | — | — | — | — | ||||||
| Humana Inc. | 1.20 | 1.32 | 1.28 | 1.26 | 1.37 | 1.47 | 1.35 | 1.29 | 1.47 | 1.51 | 1.36 | 1.32 | — | — | — | — | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 4.34 | 4.66 | 5.12 | 5.76 | 5.96 | 5.93 | 5.40 | 4.00 | 3.75 | 3.80 | 4.15 | 4.53 | — | — | — | — | — | — | — | — | ||||||
| Medtronic PLC | 1.91 | 1.58 | 1.63 | 1.37 | 1.50 | 2.05 | 2.02 | 1.95 | 1.90 | 1.69 | 1.88 | 1.83 | — | — | — | — | — | — | — | — | ||||||
| UnitedHealth Group Inc. | 0.72 | 0.71 | 0.71 | 0.68 | 0.68 | 0.75 | 0.76 | 0.66 | 0.63 | 0.64 | 0.62 | 0.66 | — | — | — | — | — | — | — | — | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 2,131,700 ÷ 1,032,300 = 2.07
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Edwards Lifesciences Corp. quick ratio deteriorated from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Cash Ratio
Edwards Lifesciences Corp., cash ratio calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Cash and cash equivalents | 862,800) | 1,506,900) | 1,312,800) | 1,174,200) | 1,183,200) | 1,024,000) | 903,500) | 662,900) | 1,179,100) | 1,186,600) | 726,800) | 709,200) | 714,100) | 1,261,300) | 1,226,400) | 1,227,000) | 818,300) | 630,300) | 508,200) | 819,300) | ||||||
| Short-term investments | 604,000) | 287,800) | 248,400) | 156,400) | 219,400) | 271,300) | 260,300) | 368,200) | 337,800) | 170,300) | 207,500) | 253,800) | 242,400) | 334,400) | 174,400) | 272,300) | 519,200) | 772,500) | 623,600) | 98,900) | ||||||
| Total cash assets | 1,466,800) | 1,794,700) | 1,561,200) | 1,330,600) | 1,402,600) | 1,295,300) | 1,163,800) | 1,031,100) | 1,516,900) | 1,356,900) | 934,300) | 963,000) | 956,500) | 1,595,700) | 1,400,800) | 1,499,300) | 1,337,500) | 1,402,800) | 1,131,800) | 918,200) | ||||||
| Current liabilities | 1,032,300) | 966,500) | 886,200) | 799,000) | 893,900) | 846,300) | 873,200) | 746,900) | 902,400) | 775,800) | 697,000) | 646,500) | 876,600) | 1,261,100) | 1,183,200) | 1,314,500) | 1,402,900) | 735,200) | 562,500) | 584,800) | ||||||
| Liquidity Ratio | ||||||||||||||||||||||||||
| Cash ratio1 | 1.42 | 1.86 | 1.76 | 1.67 | 1.57 | 1.53 | 1.33 | 1.38 | 1.68 | 1.75 | 1.34 | 1.49 | 1.09 | 1.27 | 1.18 | 1.14 | 0.95 | 1.91 | 2.01 | 1.57 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Cash Ratio, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | 0.78 | 0.75 | 0.71 | 0.67 | 0.60 | 0.46 | 0.46 | 0.34 | 0.38 | 0.41 | 0.37 | 0.36 | — | — | — | — | — | — | — | — | ||||||
| Cigna Group | 0.14 | 0.13 | 0.15 | 0.24 | 0.32 | 0.15 | 0.20 | 0.13 | 0.14 | 0.17 | 0.17 | 0.20 | — | — | — | — | — | — | — | — | ||||||
| CVS Health Corp. | 0.18 | 0.20 | 0.17 | 0.15 | 0.18 | 0.19 | 0.27 | 0.21 | 0.15 | 0.14 | 0.17 | 0.16 | — | — | — | — | — | — | — | — | ||||||
| Elevance Health Inc. | 0.95 | 0.97 | 0.97 | 1.08 | 1.04 | 1.04 | 1.10 | 0.95 | 1.08 | 1.14 | 1.07 | 1.04 | — | — | — | — | — | — | — | — | ||||||
| Humana Inc. | 1.08 | 1.20 | 1.12 | 1.12 | 1.29 | 1.39 | 1.22 | 1.16 | 1.37 | 1.44 | 1.28 | 1.15 | — | — | — | — | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 3.66 | 3.98 | 4.42 | 5.04 | 5.30 | 5.27 | 4.85 | 3.44 | 3.13 | 3.11 | 3.37 | 3.79 | — | — | — | — | — | — | — | — | ||||||
| Medtronic PLC | 1.27 | 1.17 | 1.18 | 0.99 | 1.06 | 1.33 | 1.27 | 1.25 | 1.16 | 1.03 | 1.20 | 1.21 | — | — | — | — | — | — | — | — | ||||||
| UnitedHealth Group Inc. | 0.36 | 0.35 | 0.35 | 0.33 | 0.33 | 0.37 | 0.42 | 0.35 | 0.28 | 0.30 | 0.32 | 0.32 | — | — | — | — | — | — | — | — | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 1,466,800 ÷ 1,032,300 = 1.42
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Edwards Lifesciences Corp. cash ratio improved from Q2 2021 to Q3 2021 but then deteriorated significantly from Q3 2021 to Q4 2021. |